Ivosidenib
- Generic Name
- Ivosidenib
- Brand Names
- Tibsovo
- Drug Type
- Small Molecule
- Chemical Formula
- C28H22ClF3N6O3
- CAS Number
- 1448347-49-6
- Unique Ingredient Identifier
- Q2PCN8MAM6
- Background
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells.
...
- Indication
Ivosidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor approved for use in the US and Europe. It is indicated for the treatment of patients with a susceptible IDH1 mutation with:
- Associated Conditions
- Acute Myeloid Leukemia, Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)
- Associated Therapies
- -
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT05209074
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
- Conditions
- Interventions
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT05030441
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Northwell Health Cancer Institute (R.J. Zuckerberg Cancer Center), Lake Success, New York, United States
🇺🇸Memorial Sloan Kettering, New York, New York, United States
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
- Conditions
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 125
- Registration Number
- NCT05010772
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT04955938
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 84
- Registration Number
- NCT04774393
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT04655391
- Locations
- 🇺🇸
City of Hope Meidcal Center, Duarte, California, United States
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04493164
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 25
- Registration Number
- NCT04250051
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
- Conditions
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 49
- Registration Number
- NCT04195555
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT04176393
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.